Role of Compartmentalization on HiF-1α Degradation Dynamics during Changing Oxygen Conditions: A Computational Approach

HiF-1α is the central protein driving the cellular response to hypoxia. Its accumulation in cancer cells is linked to the appearance of chemoresistant and aggressive tumor phenotypes. As a consequence, understanding the regulation of HiF-1α dynamics is a major issue to design new anti-cancer therapies. In this paper, we propose a model of the hypoxia pathway, involving HiF-1α and its inhibitor pVHL. Based on data from the literature, we made the hypothesis that the regulation of HiF-1α involves two compartments (nucleus and cytoplasm) and a constitutive shuttle of the pVHL protein between them. We first show that this model captures correctly the main features of HiF-1α dynamics, including the bi-exponential degradation profile in normoxia, the kinetics of induction in hypoxia, and the switch-like accumulation. Second, we simulated the effects of a hypoxia/reoxygenation event, and show that it generates a strong instability of HiF-1α. The protein concentration rapidly increases 3 hours after the reoxygenation, and exhibits an oscillating pattern. This effect vanishes if we do not consider compartmentalization of HiF-1α. This result can explain various counter-intuitive observations about the specific molecular and cellular response to the reoxygenation process. Third, we simulated the HiF-1α dynamics in the tumor case. We considered different types of mutations associated with tumorigenesis, and we compared their consequences on HiF-1α dynamics. Then, we tested different therapeutics strategies. We show that a therapeutic decrease of HiF-1α nuclear level is not always correlated with an attenuation of reoxygenation-induced instabilities. Thus, it appears that the design of anti-HiF-1α therapies have to take into account these two aspects to maximize their efficiency.

[1]  R. Klausner,et al.  Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein , 1999, Molecular and Cellular Biology.

[2]  S. Colgan,et al.  Induction of the von Hippel‐Lindau tumor suppressor gene by late hypoxia limits HIF‐1 expression , 2005, Journal of cellular biochemistry.

[3]  C. Michiels,et al.  Reciprocal influence of the p53 and the hypoxic pathways , 2011, Cell Death and Disease.

[4]  K. Nakanishi,et al.  Expression of hypoxia‐inducible factor‐1α in esophageal squamous cell carcinoma , 2005, Cancer science.

[5]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. , 2000, The American journal of pathology.

[6]  Murtaza M Tambuwala,et al.  A dynamic model of the hypoxia-inducible factor 1&agr; (HIF-1&agr;) network , 2013, Journal of Cell Science.

[7]  V. Grégoire,et al.  Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. , 2006, Cancer research.

[8]  Aleksander S. Popel,et al.  Three autocrine feedback loops determine HIF1α expression in chronic hypoxia , 2007 .

[9]  Till Acker,et al.  Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function , 2000, Oncogene.

[10]  Y. Miyagi,et al.  Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. , 2006, Anticancer research.

[11]  Karim Mekhail,et al.  Identification of a common subnuclear localization signal. , 2007, Molecular biology of the cell.

[12]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[13]  G. Semenza.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. , 2012, Trends in pharmacological sciences.

[14]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[15]  M. Ihnat,et al.  Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. , 2007, Cancer letters.

[16]  K. Huntoon,et al.  Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. , 2013, Cell reports.

[17]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 (HIF-1) Pathway , 2007, Science's STKE.

[18]  L. Poellinger,et al.  Cell-Type-Specific Regulation of Degradation of Hypoxia-Inducible Factor 1α: Role of Subcellular Compartmentalization , 2006, Molecular and Cellular Biology.

[19]  N. Imura,et al.  Nuclear localization of hypoxia-inducible factor-2alpha in bovine arterial endothelial cells. , 1999, Molecular cell biology research communications : MCBRC.

[20]  F. Duh,et al.  Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene , 1996, Human Genetics.

[21]  Dan Cao,et al.  Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications , 2009, BMC Cancer.

[22]  Manfred Kunz,et al.  Molecular responses to hypoxia in tumor cells , 2003, Molecular Cancer.

[23]  Mathematical modelling of the HIF-1 mediated hypoxic response in tumours , 2006 .

[24]  H. Gröne,et al.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. , 2001, Cancer research.

[25]  David I Stuart,et al.  Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. , 2002, Nature.

[26]  J. Remacle,et al.  Hypoxia stimulates human endothelial cells to release smooth muscle cell mitogens: role of prostaglandins and bFGF. , 1994, Experimental cell research.

[27]  P. Kang,et al.  Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. , 2000, Circulation research.

[28]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[29]  A. Harris,et al.  Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. , 2002, Cancer research.

[30]  H. Moch,et al.  VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. , 2011, Cancer research.

[31]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[32]  D. Long,et al.  The role of HIF-1 in up-regulating MICA expression on human renal proximal tubular epithelial cells during hypoxia/reoxygenation , 2010, BMC Cell Biology.

[33]  John N Weinstein,et al.  Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. , 2004, Molecular biology of the cell.

[34]  M. Frontini,et al.  CSB protein is (a direct target of HIF‐1 and) a critical mediator of the hypoxic response , 2008, The EMBO journal.

[35]  H. Harada,et al.  Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. , 2007, International journal of oncology.

[36]  V. Grégoire,et al.  Impact of cyclic hypoxia on HIF‐1α regulation in endothelial cells – new insights for anti‐tumor treatments , 2009, The FEBS journal.

[37]  S. Fox,et al.  Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer , 2007, Breast Cancer Research.

[38]  Stephen Lee,et al.  Oxygen-Dependent Ubiquitination and Degradation of Hypoxia-Inducible Factor Requires Nuclear-Cytoplasmic Trafficking of the von Hippel-Lindau Tumor Suppressor Protein , 2002, Molecular and Cellular Biology.

[39]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[40]  Angélique Stéphanou,et al.  On the importance of the submicrovascular network in a computational model of tumour growth. , 2012, Microvascular research.

[41]  G. Semenza,et al.  Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. , 1998, Cancer research.

[42]  R. Blasberg,et al.  Real-Time Imaging of HIF-1α Stabilization and Degradation , 2009, PloS one.

[43]  H. Kubis,et al.  Accumulation and nuclear import of HIF1 alpha during high and low oxygen concentration in skeletal muscle cells in primary culture. , 2005, Biochimica et biophysica acta.

[44]  P. V. van Diest,et al.  Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1α expression , 2011, Cellular Oncology.

[45]  M. Dewhirst.  Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. , 2007, Cancer research.

[46]  A. Cheong,et al.  Hypoxia-inducible factor (HIF) network: insights from mathematical models , 2013, Cell Communication and Signaling.

[47]  Shuai Ma,et al.  Effect of hypoxia-inducible factor 1-alpha on hypoxia/reoxygenation-induced apoptosis in primary neonatal rat cardiomyocytes. , 2012, Biochemical and biophysical research communications.

[48]  G. Semenza,et al.  Induction of HIF‐1α expression by intermittent hypoxia: Involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR , 2008, Journal of cellular physiology.

[49]  Christopher J. R. Illingworth,et al.  Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1alpha. , 2010, Biochemistry.

[50]  R. Klausner,et al.  Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Stéphanou,et al.  A mathematical model of HiF-1α-mediated response to hypoxia on the G1/S transition. , 2014, Mathematical biosciences.

[52]  G. Gores,et al.  Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. , 2005, Journal of hepatology.

[53]  J. Mehta,et al.  Hypoxia-reoxygenation-induced apoptosis in cultured adult rat myocytes and the protective effect of platelets and transforming growth factor-beta(1). , 1999, The Journal of pharmacology and experimental therapeutics.

[54]  W. Kaelin,et al.  Expression pattern of the von Hippel-Lindau protein in human tissues. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[55]  L. Rocha-Zavaleta,et al.  Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL , 2013, Leukemia & lymphoma.

[56]  Monika Heiner,et al.  Structural Analysis to Determine the Core of Hypoxia Response Network , 2010, PloS one.

[57]  M. Gassmann,et al.  HIF‐1 is expressed in normoxic tissue and displays an organ‐specific regulation under systemic hypoxia , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  S. Frede,et al.  Imaging of the hypoxia-inducible factor pathway: insights into oxygen sensing , 2008, European Respiratory Journal.

[59]  Rahul Simha,et al.  Pathway Switching Explains the Sharp Response Characteristic of Hypoxia Response Network , 2007, PLoS Comput. Biol..

[60]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[61]  P. Kronqvist,et al.  Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  Chi V. Dang,et al.  Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression* , 2001, The Journal of Biological Chemistry.

[63]  Jonathan Pevsner,et al.  HIF-dependent antitumorigenic effect of antioxidants in vivo. , 2007, Cancer cell.

[64]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[65]  P. Ratcliffe,et al.  The pVHL-hIF-1 system. A key mediator of oxygen homeostasis. , 2001, Advances in experimental medicine and biology.

[66]  Sandeep Krishna,et al.  Stress-specific response of the p53-Mdm2 feedback loop , 2010, BMC Systems Biology.

[67]  G. Semenza,et al.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. , 1996, The American journal of physiology.

[68]  K. Grankvist,et al.  Hypoxia-inducible factor-1alfa mRNA and protein levels in renal cell carcinoma , 2008 .

[69]  M. Blagosklonny.  Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors , 2001, Oncogene.

[70]  Z. Dai,et al.  Up-regulation of hypoxia inducible factor-1α by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells , 2012, Journal of Experimental & Clinical Cancer Research.

[71]  C. Hsieh,et al.  Construction of Mutant TKGFP for Real-Time Imaging of Temporal Dynamics of HIF-1 Signal Transduction Activity Mediated by Hypoxia and Reoxygenation in Tumors in Living Mice , 2009, Journal of Nuclear Medicine.

[72]  Aleksander S Popel,et al.  Three autocrine feedback loops determine HIF1 alpha expression in chronic hypoxia. , 2007, Biochimica et biophysica acta.

[73]  L. del Peso,et al.  Hypoxia Inducible Factor 1-Alpha (HIF-1 Alpha) Is Induced during Reperfusion after Renal Ischemia and Is Critical for Proximal Tubule Cell Survival , 2012, PloS one.